Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 15/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606144 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2CASP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6808253 | 0.89 | CASP1 (0.52) | SMN1; SMN2CASP1 | |
| SCHEMBL7408059 | 0.89 | SMN1; SMN2 (0.62) | SMN1; SMN2CASP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17232237 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2CASP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27895527 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL1701200 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL10884952 | 0.85 | CASP1 (0.59) | CASP1 | |
| SCHEMBL10888856 | 0.85 | CASP1 (0.59) | CASP1 | |
| SCHEMBL15722123 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL15722121 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349911-B | Nitric oxide releasing prodrug molecules | 浙江华海药业股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-10456405-B2 | Nitric oxide-releasing prodrug molecule of substituted quinazolines | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2019-10-29 | — | — | US | disclosed |
| US-20180250305-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2018-09-06 | — | — | US | disclosed |
| CN-108349911-A | Releasable nitric oxide production prodrugs | 浙江华海药业股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-3348548-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2018-07-18 | — | — | EP | disclosed |
| US-20150105547-A1 | NITRIC OXIDE RELEASING STEROIDS | NICOX S.A. (FR) | 2015-04-16 | — | — | US | disclosed |
| US-8933062-B2 | Nitric oxide releasing steroids | NICOX S.A. (FR) | 2015-01-13 | — | — | US | disclosed |
| US-20100093685-A1 | NITRIC OXIDE RELEASING STEROIDS | NICOX S.A. | 2010-04-15 | — | — | US | disclosed |
| CN-101652380-A | Discharge nitric oxide production steroid | NICOX SA FR | 2010-02-17 | — | — | CN | disclosed |
| EP-2118120-A1 | NITRIC OXIDE RELEASING STEROIDS | Nicox S.A. (FR) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008095806-A1 | NITRIC OXIDE RELEASING STEROIDS | NICOX S.A. (FR) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105547-A1 | NITRIC OXIDE RELEASING STEROIDS | NR3C1, CYP11B1, NOS1 | SMN1; SMN2 3698/4885CASP1 1307/4885CYP1A2 144/4885 |
| US-10456405-B2 | Nitric oxide-releasing prodrug molecule of substituted quinazolines | PTGIS, NOS1, NOS2 | SMN1; SMN2 3576/4885CASP1 1402/4885CYP1A2 72/4885 |
| US-20180250305-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | NOS1, NOS2, PTGIS | SMN1; SMN2 3878/4885CASP1 848/4885CYP1A2 79/4885 |
| US-20100093685-A1 | NITRIC OXIDE RELEASING STEROIDS | NR3C1, CYP11B1, NOS1 | SMN1; SMN2 4107/4885CASP1 1601/4885CYP1A2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.